|
||
Ciprofloxacin Alvia Dosage |
||
Generic name: Ciprofloxacin Alvia HYDROCHLORIDE 500mg
Dosage form: tablet, film coated, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Ciprofloxacin Alvia and other oral formulations of Ciprofloxacin Alvia are not interchangeable. Ciprofloxacin Alvia should be administered orally once daily for 3 days with a main meal of the day, preferably the evening meal. Ciprofloxacin Alvia should be administered at least 4 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, VIDEX® (didanosine) chewable/buffered tablets or pediatric powder, metal cations such as iron, and multivitamin preparations containing zinc.
Ciprofloxacin Alvia tablets should be taken whole and never split, crushed, or chewed.
Ciprofloxacin Alvia is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. No dosage adjustment is required for patient with uUTI and mild to moderate renal impairment. The efficacy of Ciprofloxacin Alvia has not been studied in patients with severe renal impairment.
No dosage adjustment is required with Ciprofloxacin Alvia in patients with stable chronic cirrhosis. However, the pharmacokinetics of Ciprofloxacin Alvia in patients with acute hepatic insufficiency have not been fully elucidated.
Do not take Ciprofloxacin Alvia together with tizanidine (Zanaflex).
Tell your doctor about all other medicines you use, especially:
This list is not complete and other drugs may interact with Ciprofloxacin Alvia. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
As with some other quinolones, concurrent administration of Ciprofloxacin Alvia with theophylline may lead to elevated serum concentrations of theophylline, which may result in an increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, serum concentrations of theophylline should be monitored and dosage adjustments made as appropriate.
Concurrent administration of quinolones, including Ciprofloxacin Alvia, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX® chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of Ciprofloxacin Alvia. Ciprofloxacin Alvia (Ciprofloxacin Alvia hcl) should be given either 2 hours after or at least 4 hours before these products. This time window is different than for other oral formulations of Ciprofloxacin Alvia, which are usually administered 2 hours before or 6 hours after antacids.
Concomitant administration of Ciprofloxacin Alvia with milk products or calcium-fortified juices alone should be avoided since decreased absorption of Ciprofloxacin Alvia is possible.
Quinolones, including Ciprofloxacin Alvia, have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be monitored if Ciprofloxacin Alvia (Ciprofloxacin Alvia hcl) is administered concomitantly with warfarin or other oral anticoagulants. Patients should also be monitored for evidence of bleeding.
Some quinolones, including Ciprofloxacin Alvia, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly. Cyclosporine whole blood trough concentrations should be monitored when given concomitantly with Ciprofloxacin Alvia (Ciprofloxacin Alvia hcl).
Renal tubular transport of methotrexate may be inhibited by concomitant administration of Ciprofloxacin Alvia, potentially leading to increased plasma concentrations of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant Ciprofloxacin Alvia therapy is indicated.
Altered serum concentrations of phenytoin (increased and decreased) have been reported in patients receiving concomitant Ciprofloxacin Alvia. Phenytoin serum concentrations should be monitored when given concomitantly with Ciprofloxacin Alvia (Ciprofloxacin Alvia hcl).
The concomitant administration of Ciprofloxacin Alvia with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.
NSAIDs in combination with very high doses of quinolones have been shown to provoke convulsions in nonclinical studies [see Nonclinical Toxicology.
Some quinolones, including Ciprofloxacin Alvia, have been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and prolongation of the serum half-life of caffeine.
Probenecid interferes with renal tubular secretion of Ciprofloxacin Alvia and produces increased concentrations of Ciprofloxacin Alvia in serum.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|